ALXO Stock Overview
A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ALX Oncology Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.51 |
| 52 Week High | US$17.83 |
| 52 Week Low | US$1.19 |
| Beta | 1.04 |
| 11 Month Change | 9.42% |
| 3 Month Change | -34.91% |
| 1 Year Change | -81.15% |
| 33 Year Change | -94.86% |
| 5 Year Change | n/a |
| Change since IPO | -94.97% |
Recent News & Updates
Recent updates
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
Sep 12ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
Jun 27ALX Oncology: Trying To Justify The Hype
Apr 18Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?
Mar 12
ALX Oncology GAAP EPS of -$0.81 misses by $0.18
Aug 08ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer
Aug 01ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer
Jun 29ALX Oncology Is Turning Into An Also-Ran In Anti-CD47
Feb 15ALX Oncology Stock: Attractive After Recent Data And Slump In Price
Nov 30ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space
Sep 08Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation
Jul 08Dosing underway in ALX Oncology's ALX148 combo study in head and neck cancer
May 10We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate
Mar 25Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like
Feb 01
ALX Oncology: All Their Eggs In The Proverbial Basket
Jan 07ALX Oncology (ALXO) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 11Shareholder Returns
| ALXO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.1% | 2.4% | 0.5% |
| 1Y | -81.1% | 15.6% | 30.7% |
Return vs Industry: ALXO underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: ALXO underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| ALXO volatility | |
|---|---|
| ALXO Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALXO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALXO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 89 | Jason Lettmann | www.alxoncology.com |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer.
ALX Oncology Holdings Inc. Fundamentals Summary
| ALXO fundamental statistics | |
|---|---|
| Market cap | US$79.64m |
| Earnings (TTM) | -US$151.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs ALXO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALXO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$151.16m |
| Earnings | -US$151.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.87 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 7.2% |
How did ALXO perform over the long term?
See historical performance and comparison